Matthew J. Ellis
Affiliations: | Baylor College of Medicine, Houston, TX |
Google:
"Matthew Ellis"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lei JT, Jaehnig EJ, Smith H, et al. (2023) The Breast Cancer Proteome and Precision Oncology. Cold Spring Harbor Perspectives in Medicine |
| Gou X, Kim BJ, Anurag M, et al. (2023) Kinome reprogramming is a targetable vulnerability in ESR1 fusion-driven breast cancer. Cancer Research |
| Anurag M, Jaehnig EJ, Krug K, et al. (2022) Proteogenomic markers of chemotherapy resistance and response in triple negative breast cancer. Cancer Discovery |
| Kalra R, Chen CH, Wang J, et al. (2022) Poziotinib inhibits HER2 mutant-driven therapeutic resistance and multi-organ metastasis in breast cancer. Cancer Research |
| Eteleeb AM, Thunuguntla PK, Gelev KZ, et al. (2022) LINC00355 regulates p27 expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer. Npj Breast Cancer. 8: 49 |
| Ademuyiwa FO, Chen I, Luo J, et al. (2021) Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Research and Treatment |
| Punturi NB, Seker S, Devarakonda V, et al. (2021) Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. Nature Communications. 12: 2940 |
| Watt AC, Cejas P, DeCristo MJ, et al. (2021) CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nature Cancer. 2: 34-48 |
| Wang X, Veeraraghavan J, Liu CC, et al. (2021) Therapeutic targeting of nemo-like kinase in primary and acquired endocrine-resistant breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Bowling EA, Wang JH, Gong F, et al. (2021) Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell |